By: IPP Bureau
Last updated : December 20, 2023 10:57 pm
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
AstraZeneca Pharma India Limited will launch Enhertu in January 2024 in India.
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.
The company has already received the Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Trastuzumab deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion (Enhertu).